Yield10 Bioscience (YTEN) Stock Forecast, Price Target & Predictions

OverviewRevenue Financials Chart Transcripts

YTEN Stock Forecast

Yield10 Bioscience stock forecast is as follows: an average price target of $7.17 (represents a 2008.51% upside from YTEN’s last price of $0.34) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

YTEN Price Target

The average price target for Yield10 Bioscience (YTEN) is $7.17 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $0.50. This represents a potential 2008.51% upside from YTEN's last price of $0.34.

YTEN Analyst Ratings

Buy

According to 1 Wall Street analysts, Yield10 Bioscience's rating consensus is 'Buy'. The analyst rating breakdown for YTEN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Yield10 Bioscience Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 26, 2024	Ben Klieve	Loop Capital Markets	$0.50	$0.33	50.33%	47.04%
Apr 21, 2022		Lake Street	$12.00	$3.59	234.26%	3428.89%
Mar 10, 2022	Anthony Vendetti	Hovde Group	$9.00	$5.40	66.67%	2546.67%

The latest Yield10 Bioscience stock forecast, released on Mar 26, 2024 by Ben Klieve from Loop Capital Markets, set a price target of $0.50, which represents a 50.33% increase from the stock price at the time of the forecast ($0.33), and a 47.04% increase from YTEN last price ($0.34).

Yield10 Bioscience Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$0.50
Last Closing Price	$0.34	$0.34	$0.34
Upside/Downside	-100.00%	-100.00%	47.04%

In the current month, the average price target of Yield10 Bioscience stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Yield10 Bioscience's last price of $0.34. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Mar 10, 2022	Maxim Group	Buy	Buy	Hold

Yield10 Bioscience's last stock rating was published by Maxim Group on Mar 10, 2022. The company gave YTEN a "Buy" rating, the same as its previous rate.

Yield10 Bioscience Financial Forecast

Yield10 Bioscience Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 16
Revenue	-	-	-	-	-	-	-	-	-	-	-	$60.00K	$87.00K	$111.00K	$103.00K	$149.00K	$152.00K	$92.00K	$174.00K	$196.00K	$195.00K	$204.00K	$221.00K	$179.00K	$140.00K	$224.00K	$318.00K	$124.00K	$285.00K	$675.00K
Avg Forecast	$2.50M	$1.50M	$295.43K	$328.20K	$364.61K	$300.00K	$375.00K	$1.88M	$33.33K	$75.00K	$33.33K	$73.33K	$112.50K	$124.67K	$159.25K	$173.00K	$97.50K	$207.00K	$192.50K	$261.67K	$253.00K	$229.50K	$182.33K	$163.00K	$206.33K	$162.50K	$140.00K	$118.33K	$326.25K	$153.33K
High Forecast	$2.50M	$1.50M	$295.43K	$328.20K	$364.61K	$300.00K	$375.00K	$1.88M	$33.33K	$75.00K	$33.33K	$73.33K	$112.50K	$124.67K	$159.25K	$173.00K	$97.50K	$207.00K	$192.50K	$261.67K	$253.00K	$229.50K	$182.33K	$163.00K	$206.33K	$162.50K	$140.00K	$118.33K	$391.50K	$184.00K
Low Forecast	$2.50M	$1.50M	$295.43K	$328.20K	$364.61K	$300.00K	$375.00K	$1.88M	$33.33K	$75.00K	$33.33K	$73.33K	$112.50K	$124.67K	$159.25K	$173.00K	$97.50K	$207.00K	$192.50K	$261.67K	$253.00K	$229.50K	$182.33K	$163.00K	$206.33K	$162.50K	$140.00K	$118.33K	$261.00K	$122.67K
# Analysts	-	-	-	-	-	1	-	-	1	-	-	-	-	-	-	-	-	-	-	9	9	8	7	6	5	5	5	5	13	11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.82%	0.77%	0.89%	0.65%	0.86%	1.56%	0.44%	0.90%	0.75%	0.77%	0.89%	1.21%	1.10%	0.68%	1.38%	2.27%	1.05%	0.87%	4.40%

Yield10 Bioscience's average Quarter revenue forecast for Jun 23 based on 0 analysts is $33.33K, with a low forecast of $33.33K, and a high forecast of $33.33K. YTEN's average Quarter revenue forecast represents a -44.45% decrease compared to the company's last Quarter revenue of $60.00K (Mar 23).

Yield10 Bioscience EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 16
# Analysts	-	-	-	-	-	1	-	-	1	-	-	-	-	-	-	-	-	-	-	9	9	8	7	6	5	5	5	5	13	11
EBITDA	-	-	-	-	-	-	-	-	$-3.25M	-	-	$-3.73M	$-3.20M	$-3.42M	$-3.37M	$-3.26M	$-2.91M	$-2.33M	$-3.03M	$-2.50M	$-2.57M	$-2.11M	$-1.75M	$-3.54M	$5.97M	$-1.93M	$-1.82M	$-2.21M	$-2.34M	$-6.38M
Avg Forecast	$-2.50M	$-1.50M	$-295.43K	$-328.20K	$-364.61K	$-300.00K	$-375.00K	$-1.88M	$-33.33K	$-75.00K	$-33.33K	$-73.33K	$-112.50K	$-3.61M	$-159.25K	$-3.16M	$-97.50K	$-207.00K	$-192.50K	$-2.32M	$-253.00K	$-229.50K	$-182.33K	$-3.27M	$-206.33K	$-162.50K	$-140.00K	$-2.31M	$-2.60M	$-6.10M
High Forecast	$-2.50M	$-1.50M	$-295.43K	$-328.20K	$-364.61K	$-300.00K	$-375.00K	$-1.88M	$-33.33K	$-75.00K	$-33.33K	$-73.33K	$-112.50K	$-2.89M	$-159.25K	$-2.53M	$-97.50K	$-207.00K	$-192.50K	$-1.86M	$-253.00K	$-229.50K	$-182.33K	$-2.62M	$-206.33K	$-162.50K	$-140.00K	$-1.84M	$-2.08M	$-4.88M
Low Forecast	$-2.50M	$-1.50M	$-295.43K	$-328.20K	$-364.61K	$-300.00K	$-375.00K	$-1.88M	$-33.33K	$-75.00K	$-33.33K	$-73.33K	$-112.50K	$-4.33M	$-159.25K	$-3.80M	$-97.50K	$-207.00K	$-192.50K	$-2.78M	$-253.00K	$-229.50K	$-182.33K	$-3.93M	$-206.33K	$-162.50K	$-140.00K	$-2.77M	$-3.12M	$-7.32M
Surprise %	-	-	-	-	-	-	-	-	97.41%	-	-	50.88%	28.48%	0.95%	21.14%	1.03%	29.89%	11.28%	15.72%	1.08%	10.15%	9.20%	9.58%	1.08%	-28.95%	11.89%	13.01%	0.96%	0.90%	1.05%

6 analysts predict YTEN's average Quarter EBITDA for Mar 20 to be $-3.27M, with a high of $-2.62M and a low of $-3.93M. This is -154.81% lower than Yield10 Bioscience's previous annual EBITDA (Dec 19) of $5.97M.

Yield10 Bioscience Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 16
# Analysts	-	-	-	-	-	1	-	-	1	-	-	-	-	-	-	-	-	-	-	9	9	8	7	6	5	5	5	5	13	11
Net Income	-	-	-	-	-	-	-	-	$-3.27M	-	-	$-3.76M	$-3.30M	$-3.49M	$-3.44M	$-3.33M	$-2.98M	$-2.40M	$-3.09M	$-2.56M	$-2.64M	$-2.17M	$-1.80M	$-3.60M	$-6.84M	$-1.98M	$-1.87M	$-2.26M	$-2.39M	$-6.50M
Avg Forecast	$-3.24M	$-2.78M	$-4.01M	$-4.01M	$-3.47M	$-3.47M	$-2.93M	$-1.70M	$-4.70M	$-6.06M	$-9.41M	$-9.77M	$-9.33M	$-3.71M	$-10.64B	$-3.23M	$-9.79B	$-10.02B	$-8.33B	$-2.38M	$-10.79B	$-14.57B	$-20.04B	$-3.33M	$-67.84B	$-101.76B	$-129.52B	$-2.36M	$-2.66M	$-6.22M
High Forecast	$-3.24M	$-2.78M	$-4.01M	$-4.01M	$-3.47M	$-3.47M	$-2.93M	$-1.70M	$-4.70M	$-6.06M	$-9.41M	$-9.77M	$-9.33M	$-2.97M	$-10.64B	$-2.58M	$-9.79B	$-10.02B	$-8.33B	$-1.90M	$-10.79B	$-14.57B	$-20.04B	$-2.66M	$-67.84B	$-101.76B	$-129.52B	$-1.89M	$-2.12M	$-4.97M
Low Forecast	$-3.24M	$-2.78M	$-4.01M	$-4.01M	$-3.47M	$-3.47M	$-2.93M	$-1.70M	$-4.70M	$-6.06M	$-9.41M	$-9.77M	$-9.33M	$-4.45M	$-10.64B	$-3.88M	$-9.79B	$-10.02B	$-8.33B	$-2.85M	$-10.79B	$-14.57B	$-20.04B	$-3.99M	$-67.84B	$-101.76B	$-129.52B	$-2.83M	$-3.19M	$-7.46M
Surprise %	-	-	-	-	-	-	-	-	0.69%	-	-	0.39%	0.35%	0.94%	0.00%	1.03%	0.00%	0.00%	0.00%	1.08%	0.00%	0.00%	0.00%	1.08%	0.00%	0.00%	0.00%	0.96%	0.90%	1.05%

Yield10 Bioscience's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. YTEN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Yield10 Bioscience SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 16
# Analysts	-	-	-	-	-	1	-	-	1	-	-	-	-	-	-	-	-	-	-	9	9	8	7	6	5	5	5	5	13	11
SG&A	-	-	-	-	-	-	-	-	$1.29M	-	-	$1.70M	$1.40M	$1.52M	$1.52M	$1.71M	$1.52M	$1.55M	$1.60M	$1.43M	$1.38M	$1.10M	$1.18M	$1.39M	$1.35M	$990.00K	$1.02M	$1.19M	$1.45M	$2.73M
Avg Forecast	$66.66M	$39.99M	$7.88M	$8.75M	$9.72M	$8.00M	$10.00M	$49.99M	$888.74K	$2.00M	$888.74K	$1.96M	$3.00M	$3.32M	$4.25M	$4.61M	$2.60M	$5.52M	$5.13M	$6.98M	$6.75M	$6.12M	$4.86M	$4.35M	$5.50M	$4.33M	$3.73M	$3.16M	$8.70M	$4.09M
High Forecast	$66.66M	$39.99M	$7.88M	$8.75M	$9.72M	$8.00M	$10.00M	$49.99M	$888.74K	$2.00M	$888.74K	$1.96M	$3.00M	$3.32M	$4.25M	$4.61M	$2.60M	$5.52M	$5.13M	$6.98M	$6.75M	$6.12M	$4.86M	$4.35M	$5.50M	$4.33M	$3.73M	$3.16M	$10.44M	$4.91M
Low Forecast	$66.66M	$39.99M	$7.88M	$8.75M	$9.72M	$8.00M	$10.00M	$49.99M	$888.74K	$2.00M	$888.74K	$1.96M	$3.00M	$3.32M	$4.25M	$4.61M	$2.60M	$5.52M	$5.13M	$6.98M	$6.75M	$6.12M	$4.86M	$4.35M	$5.50M	$4.33M	$3.73M	$3.16M	$6.96M	$3.27M
Surprise %	-	-	-	-	-	-	-	-	1.45%	-	-	0.87%	0.47%	0.46%	0.36%	0.37%	0.59%	0.28%	0.31%	0.21%	0.21%	0.18%	0.24%	0.32%	0.25%	0.23%	0.27%	0.38%	0.17%	0.67%

Yield10 Bioscience's average Quarter SG&A projection for Mar 24 is $49.99M, based on 0 Wall Street analysts, with a range of $49.99M to $49.99M. The forecast indicates a 3784.38% rise compared to YTEN last annual SG&A of $1.29M (Dec 23).

Yield10 Bioscience EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Jun 18	Mar 16
# Analysts	-	-	-	-	-	1	-	-	1	-	-	-	-	-	-	-	-	-	-	9	9	8	7	6	5	5	5	5	13	11
EPS	-	-	-	-	-	-	-	-	$-0.00	-	-	$-0.75	$-0.67	$-0.71	$-0.70	$-0.68	$-0.61	$-0.49	$-0.64	$-0.60	$-0.79	$-0.87	$-0.92	$-2.12	$-12.02	$-6.40	$-6.00	$-8.80	$-9.60	$-96.00
Avg Forecast	$-5.04	$-4.32	$-6.24	$-6.24	$-5.40	$-5.40	$-4.56	$-2.64	$-7.32	$-9.44	$-14.64	$-15.20	$-14.52	$-15.60	$-16.56	$-15.66	$-15.24	$-15.60	$-12.96	$-13.76	$-16.80	$-22.68	$-31.20	$-47.28	$-105.60	$-158.40	$-201.60	$-220.80	$-12.00	$-2.20
High Forecast	$-5.04	$-4.32	$-6.24	$-6.24	$-5.40	$-5.40	$-4.56	$-2.64	$-7.32	$-9.44	$-14.64	$-15.20	$-14.52	$-15.60	$-16.56	$-15.66	$-15.24	$-15.60	$-12.96	$-13.76	$-16.80	$-22.68	$-31.20	$-47.28	$-105.60	$-158.40	$-201.60	$-220.80	$-9.60	$-1.76
Low Forecast	$-5.04	$-4.32	$-6.24	$-6.24	$-5.40	$-5.40	$-4.56	$-2.64	$-7.32	$-9.44	$-14.64	$-15.20	$-14.52	$-15.60	$-16.56	$-15.66	$-15.24	$-15.60	$-12.96	$-13.76	$-16.80	$-22.68	$-31.20	$-47.28	$-105.60	$-158.40	$-201.60	$-220.80	$-14.40	$-2.64
Surprise %	-	-	-	-	-	-	-	-	0.00%	-	-	0.05%	0.05%	0.05%	0.04%	0.04%	0.04%	0.03%	0.05%	0.04%	0.05%	0.04%	0.03%	0.04%	0.11%	0.04%	0.03%	0.04%	0.80%	43.64%

According to undefined Wall Street analysts, Yield10 Bioscience's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to YTEN previous annual EPS of $NaN (undefined).

Yield10 Bioscience Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
AVD	American Vanguard	$4.31	$20.00	364.04%	Buy
BIOX	Bioceres Crop Solutions	$6.32	$13.30	110.44%	Buy
ICL	ICL Group	$4.98	$7.07	41.97%	Hold
MOS	Mosaic	$24.27	$34.17	40.79%	Buy
IPI	Intrepid Potash	$22.50	$31.50	40.00%	Hold
LVRO	Lavoro	$5.17	$7.00	35.40%	Buy
FMC	FMC	$49.74	$67.00	34.70%	Buy
NTR	Nutrien	$44.50	$57.71	29.69%	Buy
SMG	Scotts Miracle-Gro	$66.99	$81.00	20.91%	Hold
CTVA	Corteva	$57.48	$66.80	16.21%	Buy
CF	CF Industries	$85.40	$87.00	1.87%	Buy

YTEN Forecast FAQ

Is Yield10 Bioscience a good buy?

Yes, according to 1 Wall Street analysts, Yield10 Bioscience (YTEN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of YTEN's total ratings.

What is YTEN's price target?

Yield10 Bioscience (YTEN) average price target is $7.17 with a range of $0.5 to $12, implying a 2008.51% from its last price of $0.34. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Yield10 Bioscience stock go up soon?

According to Wall Street analysts' prediction for YTEN stock, the company can go up by 2008.51% (from the last price of $0.34 to the average price target of $7.17), up by 3428.89% based on the highest stock price target, and up by 47.04% based on the lowest stock price target.

Can Yield10 Bioscience stock reach $1?

YTEN's average twelve months analyst stock price target of $7.17 supports the claim that Yield10 Bioscience can reach $1 in the near future.

What are Yield10 Bioscience's analysts' financial forecasts?

Yield10 Bioscience's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.91M (high $2.91M, low $2.91M), average EBITDA is $-2.915M (high $-2.915M, low $-2.915M), average net income is $-11.564M (high $-11.564M, low $-11.564M), average SG&A $77.71M (high $77.71M, low $77.71M), and average EPS is $-18 (high $-18, low $-18). YTEN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $4.62M (high $4.62M, low $4.62M), average EBITDA is $-4.624M (high $-4.624M, low $-4.624M), average net income is $-14.031M (high $-14.031M, low $-14.031M), average SG&A $123.28M (high $123.28M, low $123.28M), and average EPS is $-21.84 (high $-21.84, low $-21.84).

Did the YTEN's actual financial results beat the analysts' financial forecasts?

Based on Yield10 Bioscience's last annual report (Dec 2023), the company's revenue was $60K, which missed the average analysts forecast of $215K by -72.09%. Apple's EBITDA was $-14.417M, beating the average prediction of $-215K by 6605.61%. The company's net income was $-14.455M, missing the average estimation of $-29.938M by -51.72%. Apple's SG&A was $6.15M, beating the average forecast of $5.73M by 7.35%. Lastly, the company's EPS was $-0.0018, missing the average prediction of $-46.6 by -100.00%. In terms of the last quarterly report (Mar 2023), Yield10 Bioscience's revenue was $60K, missing the average analysts' forecast of $73.33K by -18.18%. The company's EBITDA was $-3.731M, beating the average prediction of $-73.333K by 4987.75%. Yield10 Bioscience's net income was $-3.764M, missing the average estimation of $-9.765M by -61.45%. The company's SG&A was $1.7M, missing the average forecast of $1.96M by -13.16%. Lastly, the company's EPS was $-0.75, missing the average prediction of $-15.2 by -95.07%